Clinical effect of BV-araU on varicella-zoster virus infection in immunocompromised patients with haematological malignancies
- 1 March 1991
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 27 (3) , 361-367
- https://doi.org/10.1093/jac/27.3.361
Abstract
We evaluated the treatment of varicella-zoster infection with BV-araU in immunocompromised patients with haematological malignancies in a randomized controlled study. Comparison was made between doses of 150 and 30 mg/day. For ethical reasons there was no placebo group. The percentage of patients given a ‘very effective’ rating by both attending physicians and the Evaluation Committee was significantly higher in the 150 mg/day group (56.0%) compared to the 30 mg/day group (15.0%). There was no significant difference in efficacy rate (‘very effective’ plus ‘effective’) between the two groups. The incidence of side effects was low (7.8%), all were mild and disappeared on stopping treatment. These results suggest that BV-araU is clinically useful, especially at a dose of 150 mg/day in immunocompromised patients. Further comparative studies between BV-araU and acyclovir or vidarabine are indicated.Keywords
This publication has 0 references indexed in Scilit: